To access this material please log in or register

Register Authorize

Heart rate slowing therapy in patients with chronic heart failure and preserved left ventricular ejection fraction

Kanorsky S. G., Borisenko Yu. V.
State Budgetary Educational Institution of Higher Professional Education, “Kuban State Medical University” of the RF Ministry of Health Care, Sedina 4, Krasnodar 350063

Keywords: heart failure, preserved ejection fraction, ivabradine, bisoprolol, diastolic dysfunction of the left ventricle

DOI: 10.18087/rhfj.2015.6.2162

Background. Management of patients with CHF with preserved LV EF remains largely empiric because so far none of therapies has resulted in improvement of the prognosis. Aim. To compare efficacy of bisoprolol and ivabradine for long-term treatment of CHF with preserved LV EF in patients with hypertension combined with IHD. Materials and methods. A prospective, randomized study on 104 patients with FC II CHF and LV EF ≥50 %. Evaluation of clinical status, exercise tolerance, quality of life, blood level of NT-proBNP, and EchoCG parameters was performed at baseline and after 12 months of therapy. Results. As distinct from bisoprolol (n=51), ivabradine (n=53) considerably increased exercise tolerance and quality of life, decreased NT-proBNP, and improved EchoCG parameters of LV active relaxation and compliance Conclusion. In comparison with bisoprolol, ivabradine has advantages in the treatment of CHF patients with preserved LV EF.
  1. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвёртый пересмотр). Журнал Сердечная Недостаточность. 2013;14 (7):379–472.
  2. Ferrari R, Böhm M, Cleland JG, Paulis WJ, Pieske B, Rapezzi C, Tavazzi L. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail. 2015 Jul;17 (7):665–71.
  3. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 Sep 6;362 (9386):777–81.
  4. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Tailor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006 Oct;27 (19):2338–45.
  5. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359 (23):2456–67.
  6. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370 (15):1383–92.
  7. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33 (14):1787–847.
  8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al. 2013 ACCF / AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62 (16):e147–239.
  9. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40 % treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997 Jul 15;80 (2):207–9.
  10. Bergström A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail. 2004 Jun;6 (4):453–61.
  11. van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009 Jun 9;53 (23):2150–8.
  12. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If -channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013 Oct 8;62 (15):1330–8.
  13. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007 Oct;28 (20):2539–50.
  14. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009 Feb;22 (2):107–33.
  15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 Dec;18 (12):1440–63.
  16. Kishi S, Teixido-Tura G, Ning H, Venkatesh BA, Wu C, Almeida A et al. Cumulative Blood Pressure in Early Adulthood and Cardiac Dysfunction in Middle Age: The CARDIA Study. J Am Coll Cardiol. 2015 Jun 30;65 (25):2679–87.
  17. Badar AA, Perez-Moreno AC, Hawkins NM, Jhund PS, Brunton AP, Anand IS et al. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul;8 (4):717–24.
  18. Protogerou AD, Stergiou GS, Vlachopoulos C, Blache J, Achimastos A. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des. 2009;15 (3):272–89.
  19. Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD et al. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014 Jul 22;64 (3):247–52.
  20. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014 Nov;7 (6):872–81.
  21. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014 Oct;127 (10):939–53.
  22. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev. 2015 Mar;20 (2):193–201.
  23. Patel K, Fonarow GC, Ekundayo OJ, Aban IB, Kilgore ML, Love TE et al. Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. Int J Cardiol. 2014 May 15;173 (3):393–401.
  24. Food and Drug Administration. FDA approves Corlanor to treat heart failure [press release]. April 15, 2015. Доступно на: http://www.drugs.com / newdrugs / fda-approves-corlanor-ivabradine-heart-failure-4201.html.
  25. Ghio S, Magrini G, Serio A, Klersy C, Fucili A, Ronaszeki A et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J. 2006 Mar;27 (5):562–8.
  26. Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012 Feb;14 (2):219–25.
  27. Hamdani N, Paulus WJ, van Heerebeek L, Borbely A, Boontje NM, Zuidwijk MJ et al. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Eur Heart J. 2009 Aug;30 (15):1863–72.
  28. Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli JF, Berdeaux A. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002 Feb;282 (2):H672–9.
  29. Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli JF, Berdeaux A. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003 Feb;284 (2):H676–82.
  30. Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, Thuillez C. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006 Feb;61 (2):127–37.
  31. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I (f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005 Dec;26 (23):2529–36.
  32. Marazia S, Urso L, Contini M, Pano M, Zaccaria S, Lenti V et al. The role of ivabradine in cardiac rehabilitation in patients with recent coronary artery bypass graft. J Cardiovasc Pharmacol Ther. 2015 Nov;20 (6):547–53.
  33. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014 Oct 21;35 (40):2797–815.
  34. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015 Feb 10;131 (6):550–9.
  35. Gloekler S, Traupe T, Stoller M, Schild D, Steck H, Khattab A et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart. 2014 Jan;100 (2):160–6.
  36. Reil JC, Hohl M, Reil GH, Granzier HL, Kratz MT, Kazakov A et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J. 2013 Sep;34 (36):2839–49.
  37. Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, Thorin E, Asselin C et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology. 2010;117 (3):234–42.
  38. Maczewski M, Mackiewicz U. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovasc Res. 2008 Jul 1;79 (1):42–51.
  39. Estep JD. Chronic heart failure: what does the horizon look like? Curr Opin Cardiol. 2015 Jul;30 (4):344–53.
Kanorsky S. G., Borisenko Yu. V. Heart rate slowing therapy in patients with chronic heart failure and preserved left ventricular ejection fraction. Russian Heart Failure Journal. 2015;16 (6):373–378

To access this material please log in or register

Register Authorize
Ru En